International Journal of Pharmaceutical Medicine

, Volume 20, Issue 6, pp 355–359 | Cite as

China as a Growing Research Base for Innovation in Medicines Development

Special Section on Medicines Development in China Focus on China

Abstract

In the current context of China’s rapidly growing economy, multinational drug companies are investing significantly in research and development in China, a trend that has accelerated over the last 10 years. A robust regulatory framework, an abundance of highly equipped medical universities and large patient numbers in all therapy areas make China an increasingly attractive location to conduct clinical research. In addition, data from China are now accepted for inclusion in applications for market authorisation by regulatory agencies worldwide, including the Food and Drug Administration (FDA) in the US. Hence China is becoming an equal partner in global clinical development, a trend that is likely to grow significantly in the years to come.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    von Zedtwitz M. Managing foreign R and D laboratories in China. R D Manage 2004; 34 (4): 439–52CrossRefGoogle Scholar
  2. 2.
    Fisher WA, von Zedtwitz M. Chinese R and D: naissance, renaissance or mirage? R D Manage 2004; 34 (4): 349–65CrossRefGoogle Scholar
  3. 3.
    Good clinical practice (SFDA order No. 3). Effective 2003 Sep 1 [online]. Available from URL: http://www.sfda.gov.cn [Accessed 2006 Sep 8]
  4. 4.
    Regulations for the Administration of Adverse Drug Reaction Reports and Monitoring (SFDA & MOH order No. 7). Effective 2003 Mar 4 [online]. Available from URL: http://www.sfda.gov.cn [Accessed 2006 Sep 8]
  5. 5.
    Drug Registration Regulation (SFDA order No.17). Effective 2005 May 1 [online]. Available from URL: http://www.sfda.gov.cn [Accessed 2006 Sep 8]

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Novartis ChinaBeijingPeople’s Republic of China
  2. 2.Novartis Pharma A.G.BaselSwitzerland

Personalised recommendations